Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.39 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.34 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.34 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ARG1 | P05089 | 1/20 | 0.31 |
| ▸ | ARG2 | P78540 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15905729 | 0.79 | APAF1 (0.41) | GABRR1APAF1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL17266187 | 0.73 | APAF1 (0.38) | GABRR1APAF1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL21787520 | 0.73 | APAF1 (0.38) | GABRR1APAF1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL28643146 | 0.72 | ANPEP (0.37) | CPA1CYP2D6CYP2C19 | |
| SCHEMBL27546706 | 0.72 | — | — | |
| SCHEMBL12228330 | 0.71 | APAF1 (0.39) | GABRR1APAF1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL22034668 | 0.71 | ADRB2 (0.39) | GABRR1APAF1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL11307127 | 0.71 | APAF1 (0.36) | GABRR1APAF1CYP1A2FOLH1NAALAD2 | |
| SCHEMBL904646 | 0.70 | GABRR1 (0.50) | GABRR1CYP1A2FOLH1NAALAD2ENPEP | |
| SCHEMBL2037660 | 0.70 | GABRR1 (0.50) | GABRR1CYP1A2FOLH1NAALAD2ENPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295711-A1 | COMPOSITIONS AND METHODS FOR SEQUENCING USING AT LEAST ELECTRICAL CHARACTERISTICS | ILLUMINA, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| EP-4172365-A1 | COMPOSITIONS AND METHODS FOR SEQUENCING USING AT LEAST ELECTRICAL CHARACTERISTICS | Illumina, Inc. (US) | 2023-05-03 | — | — | EP | disclosed |
| CN-115843316-A | Compositions and methods for sequencing using at least electrical properties | 伊鲁米纳公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2022005868-A1 | COMPOSITIONS AND METHODS FOR SEQUENCING USING AT LEAST ELECTRICAL CHARACTERISTICS | ILLUMINA, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20100069491-A1 | LIPID-AMINO ACID CONJUGATES AND METHODS OF USE | UNIVERSITY OF MASSACHUSETTS (US) | 2010-03-18 | — | — | US | disclosed |
| US-7544714-B2 | Lipid-amino acid conjugates and methods of use | UNIVERSITY OF MASSACHUSETTS (US) | 2009-06-09 | — | — | US | disclosed |
| CN-101068537-A | Lipid-amino acid conjugates and methods of use thereof | UNIV MASSACHUSETTS (US) | 2007-11-07 | — | — | CN | disclosed |
| EP-1778210-A2 | LIPID-AMINO ACID CONJUGATES AND METHODS OF USE | University of Massachusetts (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006010153-A2 | LIPID-AMINO ACID CONJUGATES AND METHODS OF USE | UNIVERSITY OF MASSACHUSETTS (US) | 2006-01-26 | — | — | WO | disclosed |
| US-20060014820-A1 | Lipid-amino acid conjugates and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014820-A1 | Lipid-amino acid conjugates and methods of use | SLC27A2, SLC27A1, FABP2 | GABRR1 646/4885APAF1 3313/4885CYP1A2 1210/4885 |
| US-20100069491-A1 | LIPID-AMINO ACID CONJUGATES AND METHODS OF USE | SLC27A2, SLC27A1, FABP2 | GABRR1 646/4885APAF1 3313/4885CYP1A2 1210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.